Ertapenem and meropenem:

Feature Ertapenem Meropenem
Class Carbapenem antibiotic Carbapenem antibiotic
Spectrum Broad, but lacks activity against Pseudomonas aeruginosa, Acinetobacter spp., and Enterococcus spp. Very broad, including Pseudomonas, Acinetobacter, and some Enterococcus
Gram-Positive Coverage Good activity vs. MSSA, Streptococcus Good activity vs. MSSA, Streptococcus, Enterococcus faecalis (limited)
Gram-Negative Coverage Covers Enterobacteriaceae, ESBL-producing organisms Covers Enterobacteriaceae, ESBL, plus Pseudomonas and Acinetobacter
Anaerobic Coverage Excellent (e.g., Bacteroides fragilis) Excellent
Indications Intra-abdominal infections, skin/soft tissue infections, community-acquired pneumonia, complicated UTIs, prophylaxis for colorectal surgery Severe hospital-acquired infections, meningitis, febrile neutropenia, intra-abdominal infections, skin/soft tissue infections, complicated UTIs, pneumonia (including HAP/VAP)
CNS Penetration Limited → not used for meningitis Good penetration → used for meningitis
Half-life ~4 hours (longer) ~1 hour
Dosing (Adults) 1 g IV once daily 1 g IV q8h (standard); 2 g IV q8h for meningitis
Renal Dose Adjustment Required if CrCl <30 mL/min Required if CrCl <50 mL/min
Route IV or IM IV only
Adverse Effects Similar to meropenem: seizures (rare), GI upset, hypersensitivity Similar; slightly lower seizure risk than imipenem
Clinical Pearls Convenient once-daily dosing, but avoid in suspected/confirmed Pseudomonas, Acinetobacter, or meningitis Preferred in critically ill or neutropenic patients due to broader coverage and CNS activity

Summary for pharmacists:

  • Ertapenem = broad-spectrum, once-daily dosing, good for community-acquired and polymicrobial infections, but not for Pseudomonas/Acinetobacter/meningitis.
  • Meropenem = broader spectrum, including Pseudomonas and CNS penetration, making it the go-to for hospital-acquired, severe, or resistant infections.